Positive selection of EqCD8+ precursors increases equine lymphokine-activated killing.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Positive selection of EqCD8+ precursors increases equine lymphokine-activated killing.

Vet Immunol Immunopathol. 1996 Sep;53(1-2):1-13. Unique Identifier : AIDSLINE MED/97097306
Lunn DP; Schram BR; Vagnoni KE; Schobert CS; Horohov DW; Ginther OJ; Department of Medical Sciences, School of Veterinary Medicine,; University of Wisconsin, Madison 53706, USA.

Abstract: Lymphokine activated killing (LAK) is an example of natural cytotoxicity, and as such is a critical means of defense against diseases such as viral infection and neoplasia. Despite this important role, the specific molecular interactions involved in LAK or other forms of natural cytotoxicity are only partially understood. In some species, cells capable of mediating natural cytotoxicity express the CD8 molecule, although no specific role has been demonstrated for CD8 in non-MHC restricted cytotoxicity. In this study the role of the EqCD8 equine homolog of CD8 in LAK cell activity was examined. A series of LAK assays were performed using equine lymphocyte populations enriched or depleted for EqCD8 expression by positive or negative selection. The results indicate that positive selection of LAK precursors using an anti-EqCD8 (CVS8) antibody greatly increases LAK cytotoxicity. The implications for the role of the EqCD8 molecules in LAK are discussed.

Keywords: *Antigens, CD8/IMMUNOLOGY *Cytotoxicity, Immunologic/IMMUNOLOGY *CD8-Positive T-Lymphocytes/IMMUNOLOGY *Hematopoietic Stem Cells/IMMUNOLOGY *Killer Cells, Lymphokine-Activated/IMMUNOLOGY *Lymphocyte Transformation/IMMUNOLOGY
970530
M9751671

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .